Mavacamten No Match for Nonobstructive HCM in Phase III Trial

(MedPage Today) — MADRID — Mavacamten (Camzyos) failed to replicate its previous successes in hypertrophic cardiomyopathy (HCM) when applied to a population with symptomatic, nonobstructive disease, the phase III ODYSSEY-HCM trial showed….